CuraGen Looking at 'Strategic Options' for 454 as Unit's Revenues Soar in Q2 | GenomeWeb

NEW YORK (GenomeWeb News) – CuraGen hired investment bank Goldman Sachs “to examine strategic options" for its investment in 454 Life Sciences, the company said today.
It did not provide additional information about this new strategy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.